T-DXd: ' Remarkable ' Survival Gains in Advanced Breast Cancer T-DXd: ' Remarkable ' Survival Gains in Advanced Breast Cancer

The antibody-drug conjugate trastuzumab deruxtecan continues to show impressive progression-free and overall survival gains in previously treated unresectable and/or metastatic HER2+ breast cancer.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news